Expand SYRE Menu
SYRE MENU

SYRE Latest Press Releases

-- July 2, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- June 15, 2026 --

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients Globe Newswire 8:00 AM

-- June 5, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:01 PM

-- June 3, 2026 --

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA Globe Newswire 8:00 AM

-- May 28, 2026 --

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation Globe Newswire 8:35 AM

-- May 26, 2026 --

Spyre Therapeutics to Participate in Upcoming June Investor Conferences Globe Newswire 4:10 PM

-- May 5, 2026 --

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- May 1, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:28 PM

-- April 16, 2026 --

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million Globe Newswire 4:15 PM

-- April 14, 2026 --

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock Globe Newswire 10:38 PM

-- April 13, 2026 --

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock Globe Newswire 4:46 PM
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients Globe Newswire 7:00 AM

-- April 10, 2026 --

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 Globe Newswire 4:05 PM

-- April 3, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:01 PM

-- March 16, 2026 --

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 Globe Newswire 8:00 AM

-- March 6, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- February 24, 2026 --

Spyre Therapeutics to Participate in Upcoming March Investor Conferences Globe Newswire 4:05 PM

-- February 19, 2026 --

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Globe Newswire 4:02 PM

-- February 18, 2026 --

Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes